Atopic dermatitis (eczema) trials in Germany

In Germany 32 Also abroad 251

32 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Where
Buxtehude, Dresden, Mainz, Osnabrueck, Potsdam, Tuebingen, Wuppertal
Age
6 months to 11 years
People
195 worldwide
Run by
LEO Pharma
See details and how to joinNCT06311682 · EU 2023-503630-44-00
Phase 3Taking people
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Where
Dresden, Muenster
Age
2 years to 11 years
People
450 worldwide
Run by
Pfizer
See details and how to joinNCT06807281 · EU 2023-509124-18-00
Phase 2Taking people
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Where
Friedrichshafen, Kiel, Luebeck, Muenster
Age
18 years to 64 years
People
165 worldwide
Run by
Pfizer
See details and how to joinNCT07216027 · EU 2025-522965-31-00
No phaseNot yet taking people in Germany
Localized Aeroallergen Exposure in Atopic Dermatitis
Where
Hanover
Age
18 years to 65 years
People
15
Run by
Fraunhofer-Institute of Toxicology and Experimental Medicine
See details and how to joinNCT07918586
Phase 2Taking people
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Where
Augsburg, Bad Bentheim, Berlin, Blankenfelde-Mahlow, Darmstadt, Dresden, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel, München, Münster, Tübingen
Age
18 years and over
People
350 worldwide
Run by
Apogee Therapeutics, Inc.
See details and how to joinNCT07003425
No phaseTaking people
ADBest TREAT Registry
Where
Hamburg
Age
18 years and over
People
5,000
Run by
Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT07904546
Phase 2Taking people
A Phase 2b Study of the Effects of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis
Where
Bad Bentheim, Dresden, Frankfurt Am Main, Hamburg, Luebeck, Muenster
Age
18 years and over
People
138 worldwide
Run by
Apollo Therapeutics Limited
See details and how to join2026-525673-39-00 · EU 2026-525673-39-00
Phase 3Taking people
Clinical study to compare two cutaneous creams with the active substance methylprednisolone aceponate 0.1% and one cutaneous cream without active substance for patients with atopic dermatitis
Where
Berlin, Bonn, Crimmitschau, Halle, Ibbenbüren, Kiel, Potsdam, Simmern, Vechta
People
330
Run by
Dermapharm AG
See details and how to join2024-511390-30-00 · EU 2024-511390-30-00
Phase 3Enrolling by invitation
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Where
Bad Bentheim, Darmstadt, Dresden, Frankfurt Am Main, Münster
Age
6 months to 18 years
People
338 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05735483 · EU 2022-501478-21-00
No phaseTaking people
Microbiome in Atopic Dermatitis Under Systemic Therapy
Where
Berlin
Age
18 years and over
People
600
Run by
Charite University, Berlin, Germany
See details and how to joinNCT05099315
Phase 3Taking people
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Where
Aachen, Berlin, Bochum, Dresden, Hamburg, Heidelberg, Kiel, Leipzig, Muenster, Osnabrueck, Stuttgart, Wuppertal
Age
12 years and over
People
510 worldwide
Run by
Nektar Therapeutics
See details and how to joinNCT07690371 · EU 2025-524925-42-00
Phase 3Not yet taking people in Germany
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
Where
Augsburg, Bad Bentheim, Berlin, Bochum, Cologne, Dresden, Duesseldorf, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Hamburg, Hanover, Heidelberg, Kiel, Luebeck, Mainz, Muenster, Munich, Regensburg, Rostock, Tuebingen
Age
12 years and over
People
230 worldwide
Run by
Almirall, S.A.
See details and how to joinNCT07873801 · EU 2025-525133-31-00
Phase 2Not yet taking people in Germany
A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
Where
Berlin, Frankfurt Am Main, Hamburg, Kiel, Luebeck, Muenster
Age
18 years and over
People
96 worldwide
Run by
Enveda Therapeutics Inc.
See details and how to join2026-526184-38-00 · EU 2026-526184-38-00
Phase 2Taking people
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Where
Bad Bentheim, Dresden, Frankfurt Am Main, Goettingen, Hamburg, Heidelberg, Magdeburg, Mainz Bretzenheim, Muenster, Oldenburg, Osnabrueck
Age
18 years to 100 years
People
224 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06947993 · EU 2024-519081-49-00
Phase 3Taking people
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Where
Dresden, Muenster
Age
6 years to 11 years
People
150 worldwide
Run by
Pfizer
See details and how to joinNCT06807268 · EU 2023-509121-51-00
Phase 3Taking people
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Where
Ahaus, Augsburg, Bad Bentheim, Berlin, Goettingen, Halle (Saale), Hamburg, Langenau, Merzig, Munich, Oldenburg, Regensburg, Tuebingen
Age
12 years and over
People
510 worldwide
Run by
Nektar Therapeutics
See details and how to joinNCT07711418 · EU 2025-525129-11-00
Phase 1Taking people
A first-in-human, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.
Where
Bad Bentheim, Berlin, Dresden, Mainz
Age
18 years to 64 years
People
80 worldwide
Run by
Egle Therapeutics
See details and how to join2025-521658-40-00 · EU 2025-521658-40-00
No phaseTaking people
Determinants of Chronic Inflammatory Skin Disease Trajectories
Where
Kiel
Age
0 years to 80 years
People
1,000
Run by
University Hospital Schleswig-Holstein
See details and how to joinNCT05928169
Phase 2Taking people
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Where
Bad Bentheim, Dresden, Frankfurt, Hamburg, Lübeck, Münster, Witten
Age
18 years to 65 years
People
280 worldwide
Run by
Apollo Therapeutics Ltd
See details and how to joinNCT07599813
Phase 2Taking people
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
Where
Augsburg, Bad Bentheim, Berlin, Blankenfelde-Mahlow, Darmstadt, Dresden, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel, Luebeck, Muenster, Munich, Tuebingen
Age
18 years and over
People
175 worldwide
Run by
Apogee Therapeutics Inc.
See details and how to join2024-519795-11-00 · EU 2024-519795-11-00
Phase 3Taking people
A Study of Lebrikizumab in Adults With Nummular Eczema
Where
Freiburg im Breisgau
Age
18 years and over
People
270
Run by
Almirall, S.A.
See details and how to joinNCT07542483 · EU 2025-522403-17-00
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Where
Augsburg, Bad Bentheim, Berlin, Darmstadt, Dresden, Frankfurt Am Main, Hamburg, Luebeck, Muenster, Tuebingen
Age
18 years to 74 years
People
405 worldwide
Run by
Inmagene LLC
See details and how to joinNCT07037901 · EU 2024-520117-50-00
No phaseTaking people
Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function
Where
Berlin, Düsseldorf, Frankfurt, Spandau, Wesel
Age
1 day to 14 days
People
400 worldwide
Run by
Société des Produits Nestlé (SPN)
See details and how to joinNCT06943469
No phaseEnrolling by invitation
Real-World Evidence: Effectiveness and Safety of Chronic Hand Eczema Treatment With Delgocitinib Cream
Where
Neu-Isenburg
Age
18 years and over
People
1,000
Run by
LEO Pharma
See details and how to joinNCT07603193
Phase 1Taking people
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Where
Berlin, Frankfurt, Freiburg im Breisgau
Age
18 years to 65 years
People
149 worldwide
Run by
Sitryx Therapeutics Ltd
See details and how to joinNCT07558668